44981-87-5

Upstream product

• 107-11-9 1-amino-2-propene 
• 79-10-7 acrylic acid 
• 140-88-5 ethyl acrylate 

Downstream Products

• 97579-85-6 2-(N-allyl-N-phenoxycarbonylamino)-1-ethoxycarbonylethane 
• 1026809-37-9 4-{(E)-2-[Allyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-propenyl}-benzoic acid benzyl ester 
• 851593-73-2 allyl-[3-(4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-carbamic acid tert-butyl ester 
• 851593-75-4 (R)-3-((R)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2,3,4,7-tetrahydro-azepine-1-carboxylic acid tert-butyl ester 
• 851593-74-3 Allyl-[(R)-2-((R)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-pent-4-enyl]-carbamic acid tert-butyl ester 
• 97579-89-0 3-(Allyl-phenoxycarbonyl-amino)-2-bromo-propionic acid ethyl ester 
• 97579-93-6 2-(N-allyl-N-phenoxycarbonylamino)-1-ethoxycarbonyl-1-iodoethane 
• 97579-97-0 3-ethoxycarbonyl-4-iodomethyl-1-phenoxycarbonylpyrrolidine 
• 97579-97-0 3-ethoxycarbonyl-4-iodomethyl-1-phenoxycarbonylpyrrolidine 
• 1419222-29-9 (R)-1-(benzyloxycarbonyl)azepane-3-carboxylic acid 
• 183888-16-6 3-(allyl((benzyloxy)carbonyl)amino)propanoic acid 
• 1419222-25-5 benzyl allyl((R)-2-((R)-4-benzyl-2-oxooxazolidine-3-carbonyl)pent-4-enyl)carbamate 
• 1419222-27-7 (R,Z)-1-(benzyloxycarbonyl)-2,3,4,7-tetrahydro-1H-azepine-3-carboxylic acid 
• 1419222-28-8 (R)-azepane-3-carboxylic acid 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Aza-Michael mono-addition using acidic alumina under solventless conditions

Aza-Michael reactions between primary aliphatic and aromatic amines and various Michael acceptors have been performed under environmentally-friendly solventless conditions using acidic alumina as a heterogeneous catalyst to selectively obtain the corresponding mono-adducts in high yields. Ethyl acrylate was the main acceptor used, although others such as acrylonitrile, methyl acrylate and acrylamide were also utilized successfully. Bi-functional amines also gave the mono-adducts in good to excellent yields. Such compounds can serve as intermediates for the synthesis of anti-cancer and antibiotic drugs.

PHARMACEUTICAL COMPOUNDS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Lipase-catalyzed aza-michael reaction on acrylate derivatives

A methodology has been developed for an efficient and selective lipase-catalyzed aza-Michael reaction of various amines (primary and secondary) with a series of acrylates and alkylacrylates. Reaction parameters were tuned, and under the optimal conditions it was found that Pseudomonas stutzeri lipase and Chromobacterium viscosum lipase showed the highest selectivity for the aza-Michael addition to substituted alkyl acrylates. For the first time also, some CLEAs were examined that showed a comparable or higher selectivity and yield than the free enzymes and other formulations.

Lewis acid-assisted olefin cross-metathesis reaction: An efficient approach for the synthesis of glycosidic-pyrroloquinolinone based novel building blocks of camptothecin and evaluation of their antitumor activity

A series of glycosidic-pyrroloquinolinone based novel building blocks of camptothecin (2a-g) were synthesized via Lewis acid-assisted olefin cross-metathesis reaction using Ti(OiPr)4 30 mol % and 10 mol % of Grubb's second generation catalyst with good to excellent yields. Most of these compounds exhibited significant growth inhibitory effects on all the tested cancer cell lines and three compounds (2c, 2d and 2e) showed potent cytotoxic activity.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

Chemoenzymatic synthesis with lipase catalyzed resolution and evaluation of antitumor activity of (R/S)-2-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1H- pyrrolo[3,4-b]quinolin-3(2H)-one

Synthesis, characterization, resolution and evaluation of novel (R/S)-2-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1H-pyrrolo[3,4-b] quinolin-3(2H)-one derivatives are described. Enantiomerically pure compounds were isolated in good to excellent yield w

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.